Clinical Trial Update: Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether adding immune checkpoint inhibitors to platinum-based chemotherapy improves outcomes in EGFR/ALK/ROS1-mutant non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Platinum-based chemotherapy plus immune checkpoint inhibitors

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING